Saniona A/s

Solural Pharma Aps

Oncoral Pharma Aps

Contera Pharma A/s

Conrig Pharma Aps

Ascelia Pharma Ab

Synact Pharma Aps

Bent Højgaard

John Bondo Hansen

Thomas Boesen

Peter G Nielsen

Mikael S Thomsen

Thomas Engelbrecht Nordkild Jonassen

Mikael Søndergård Thomsen

Ann Vivian Fullerton

Magnus Olafsson Corfitzen

Dorthe Da Graca Couto Thrige

Peter Gudmund Nielsen

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity, or an obesity associated disorder.

Tesofensine and beta blocker combination formulations

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

Pulsatile drug delivery system for treating morning akinesia

Provided is a pharmaceutical composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof that provides for a constant exposure of the compound.

Composition comprising suplatast tosilate

The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.

Solid oral dosage form of lipophilic compounds

The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.

Compressed solid composition for MRI

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.

Tesofensine, beta blocker combination formulation

The present invention relates to a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I, as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I); and typically wherein the composition is coated with an enteric coating. Such composition is particularly useful in treatment of cancer. 

Growing community of inventors

Allerød, Denmark

Bent Højgaard